{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:02:21Z","timestamp":1789556541224,"version":"build-2803163510"},"reference-count":203,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Human papillomavirus (HPV) is the principal etiological factor in the majority of cervical, oropharyngeal, anal, and vulvar cancers. Persistent infection with high-risk HPV types promotes immune evasion, malignant transformation, and tumor progression. Currently licensed prophylactic HPV vaccines, based on L1 virus-like particles, are highly effective at preventing new infections and HPV-associated neoplastic disease through the induction of neutralizing antibodies. However, they do not eradicate established infections or preexisting lesions. These limitations have driven the development of therapeutic HPV vaccines and adoptive T-cell strategies aimed at eliciting robust cell-mediated immunity against HPV-associated malignancies. The viral oncoproteins E6 and E7 are attractive therapeutic targets. They disrupt cell-cycle control and are consistently expressed in HPV-driven precancerous and cancerous lesions. In this review, we provide a comprehensive overview of therapeutic HPV vaccines\u2014including viral and bacterial vectors, DNA and RNA constructs, peptide\/protein vaccines, and cell-based approaches\u2014all designed to target E6 and E7, while considering the benefits and limitations of each platform. We also present an in-depth analysis of adoptive T-cell therapies, highlighting Immuno-STAT, a peptide\u2013HLA fusion platform for the direct expansion of HPV-specific CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells. Furthermore, we discuss rational combination strategies that integrate these modalities with immune checkpoint inhibitors and other immunomodulatory agents, including the bifunctional PD-L1\/TGF-\u03b2 inhibitor bintrafusp alfa, to overcome key barriers and enhance clinical efficacy. Overall, this review synthesizes current evidence and outlines future directions for the development of more precisely tailored HPV-specific immunotherapies in cancer treatment.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1897025","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:06:18Z","timestamp":1789553178000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in immunotherapy for HPV-associated malignancies: emerging strategies and clinical progress"],"prefix":"10.3389","volume":"17","author":[{"given":"Alaa","family":"Alsalloum","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology","place":["Novosibirsk, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Zakhareva","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology","place":["Novosibirsk, Russia"]},{"name":"Department of Natural Sciences, Novosibirsk State University","place":["Novosibirsk, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lopatnikova","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology","place":["Novosibirsk, Russia"]},{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Sechenov University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Sennikov","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology","place":["Novosibirsk, Russia"]},{"name":"Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Sechenov University","place":["Moscow, Russia"]},{"name":"Department of Immunology, Institute of Medicine and Medical Technologies, Novosibirsk State University","place":["Novosibirsk, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0b013e31825caa36","article-title":"HPV: diagnosis, prevention, and treatment","volume":"55","author":"Hathaway","year":"2012","journal-title":"Clin Obstet Gynecol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000193","article-title":"The estimated lifetime probability of acquiring human papillomavirus in the United States","volume":"41","author":"Chesson","year":"2014","journal-title":"Sex Transm Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/v9080229","article-title":"Targeting persistent human papillomavirus infection","volume":"9","author":"Shanmugasundaram","year":"2017","journal-title":"Viruses"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0370","article-title":"Biological and clinical aspects of HPV-related cancers","volume":"17","author":"Szymonowicz","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-66800-5_1","article-title":"Human papillomaviruses and their possible role in squamous cell carcinomas BT - Current topics in microbiology and immunology","volume-title":"Current Topics in Microbiology and Immunology","author":"zur Hausen","year":"1977"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2169","article-title":"Regulation of autophagy by high- and low-risk human papillomaviruses","volume":"31","author":"Aranda-Rivera","year":"2021","journal-title":"Rev Med Virol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41579-021-00617-5","article-title":"Human papillomaviruses: diversity, infection and host interactions","volume":"20","author":"McBride","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41598-024-51594-7","article-title":"High rate of non-vaccine targeted high-risk HPV genotypes circulate among women in Eastern Ethiopia","volume":"14","author":"Seyoum","year":"2024","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/jnci\/87.11.796","article-title":"Prevalence of human papillomavirus in cervical cancer: a worldwide perspective","volume":"87","author":"Bosch","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1973","article-title":"How will HPV vaccines affect cervical cancer","volume":"6","author":"Roden","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2013.11.002","article-title":"The human papillomavirus family and its role in carcinogenesis","volume":"26","author":"Tommasino","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev A Publ Am Assoc Cancer Res cosponsored by Am Soc Prev Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2022.102140","article-title":"Global burden of oropharyngeal cancer attributable to human papillomavirus by anatomical subsite and geographic region","volume":"78","author":"Lu","year":"2022","journal-title":"Cancer Epidemiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-1702(02)00190-9","article-title":"Human papillomavirus immortalization and transformation functions","volume":"89","author":"M\u00fcnger","year":"2002","journal-title":"Virus Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1982.tb01152.x","article-title":"Human papillomavirus 1a complete DNA sequence: a novel type of genome organization among papovaviridae","volume":"1","author":"Danos","year":"1982","journal-title":"EMBO J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02726-07","article-title":"Arrangement of L2 within the Papillomavirus Capsid","volume":"82","author":"BC","year":"2008","journal-title":"J Virol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.40.3.886-891.2002","article-title":"Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique","volume":"40","author":"Panu","year":"2002","journal-title":"J Clin Microbiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.69.5.2989-2997.1995","article-title":"Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells","volume":"69","author":"Jeon","year":"1995","journal-title":"J Virol"},{"key":"B19","article-title":"Physical state & copy number of high risk human papillomavirus type 16 DNA in progression of cervical cancer","volume-title":"Indian J Med Res","author":"Shukla","year":"2014"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.13.10.6501-6508.1993","article-title":"Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein","volume":"13","author":"Helin","year":"1993","journal-title":"Mol Cell Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.10.4549","article-title":"Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product","volume":"89","author":"Chellappan","year":"1992","journal-title":"Proc Natl Acad Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.2537532","article-title":"The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product","volume":"243","author":"Dyson","year":"1989","journal-title":"Science"},{"key":"B23","article-title":"E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway","volume":"56","author":"Boyer","year":"1996","journal-title":"Cancer Res"},{"key":"B24","article-title":"Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein","volume":"13","author":"Zerfass-Thome","year":"1996","journal-title":"Oncogene"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1101\/gad.11.16.2101","article-title":"The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2","volume":"11","author":"Jones","year":"1997","journal-title":"Genes Dev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1991.tb04990.x","article-title":"A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18","volume":"10","author":"Huibregtse","year":"1991","journal-title":"EMBO J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0092-8674(93)90384-3","article-title":"The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53","volume":"75","author":"Scheffner","year":"1993","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1186\/s12879-019-4696-6","article-title":"Human papillomavirus genotypes and P16INK4A expression in squamous penile carcinoma in Mexican patients","volume":"19","author":"Mart\u00ednez-Bail\u00f3n","year":"2019","journal-title":"BMC Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1044-579X(02)00100-1","article-title":"Human papillomavirus-induced carcinogenesis and the ubiquitin\u2013proteasome system","volume":"13","author":"Scheffner","year":"2003","journal-title":"Semin Cancer Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.12.6957-6964.2003","article-title":"The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6\u2019s induction of epithelial hyperplasia in vivo","volume":"77","author":"Nguyen","year":"2003","journal-title":"J Virol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00809","article-title":"Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes","volume":"116","author":"Watson","year":"2003","journal-title":"J Cell Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.20.9680-9693.2000","article-title":"Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins","volume":"74","author":"Lee","year":"2000","journal-title":"J Virol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22064","article-title":"HPV16-E6 associated hTERT promoter acetylation is E6AP dependent, increased in later passage cells and enhanced by loss of p300","volume":"119","author":"James","year":"2006","journal-title":"Int J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0906357106","article-title":"HPV E6 protein interacts physically and functionally with the cellular telomerase complex","volume":"106","author":"Liu","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-140","article-title":"Papillomavirus E5: the smallest oncoprotein with many functions","volume":"10","author":"Venuti","year":"2011","journal-title":"Mol Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1264777","article-title":"HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy","volume":"13","author":"Paolini","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60947-7","article-title":"Papillomavirus vaccines in perspective","volume":"369","author":"Kahn","year":"2007","journal-title":"Lancet (London England)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100055","article-title":"GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side","volume":"81","author":"Shi","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868030-00007","article-title":"Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix","volume":"68","author":"Keam","year":"2008","journal-title":"Drugs"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.06.002","article-title":"An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results","volume":"26","author":"Schiller","year":"2008","journal-title":"Vaccine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"9214","DOI":"10.3390\/ijms26189214","article-title":"From viral infection to genome reshaping: The triggering role of HPV integration in cervical cancer","volume":"26","author":"Li","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2012.744393","article-title":"Emerging human papillomavirus vaccines","volume":"17","author":"Ma","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2174\/1874357901206010241","article-title":"The immune response to papillomavirus during infection persistence and regression","volume":"6","author":"Hibma","year":"2012","journal-title":"Open Virol J"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.23.14852-14862.2005","article-title":"Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6\/E7 is related to reduced macrophage inflammatory protein-3alpha production","volume":"79","author":"Guess","year":"2005","journal-title":"J Virol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.15.8378-8385.2003","article-title":"Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin","volume":"77","author":"Matthews","year":"2003","journal-title":"J Virol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31027","article-title":"Immune evasion mechanisms of human papillomavirus: An update","volume":"142","author":"Steinbach","year":"2018","journal-title":"Int J Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00653","article-title":"The double-edged sword-how human papillomaviruses interact with immunity in head and neck cancer","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"B49","article-title":"Frequent display of human papillomavirus type 16 E6-specific memory t-helper cells in the healthy population as witness of previous viral encounter","volume":"63","author":"Welters","year":"2003","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2916","article-title":"HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions","volume":"13","author":"Peng","year":"2007","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/1541-7786.MCR-17-0153","article-title":"HPV integration in HNSCC correlates with survival outcomes, immune response signatures, and candidate drivers","volume":"16","author":"Koneva","year":"2018","journal-title":"Mol Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01053-10","article-title":"CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV","volume":"84","author":"Miura","year":"2010","journal-title":"J Virol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/156800907780006869","article-title":"Mechanisms used by human papillomaviruses to escape the host immune response","volume":"7","author":"Kanodia","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.19.10186-10201.2003","article-title":"Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers","volume":"77","author":"Middleton","year":"2003","journal-title":"J Virol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41199-018-0039-3","article-title":"HPV-driven oropharyngeal cancer: current knowledge of molecular biology and mechanisms of carcinogenesis","volume":"3","author":"Pan","year":"2018","journal-title":"Cancers Head Neck"},{"key":"B56","article-title":"Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes","volume":"59","author":"Klaes","year":"1999","journal-title":"Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2016.27.e51","article-title":"Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research","volume":"27","author":"Lee","year":"2016","journal-title":"J Gynecol Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12929-016-0293-9","article-title":"Perspectives for therapeutic HPV vaccine development","volume":"23","author":"Yang","year":"2016","journal-title":"J BioMed Sci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-017-0952-8","article-title":"Current status and future prospects for human papillomavirus vaccines","volume":"40","author":"Kim","year":"2017","journal-title":"Arch Pharm Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2016.1176533","article-title":"Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies","volume":"15","author":"Vici","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.152.8.3904","article-title":"Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins","volume":"152","author":"Kast","year":"1994","journal-title":"J Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2165\/11532810-000000000-00000","article-title":"Immunotherapy for cervical cancer: research status and clinical potential","volume":"24","author":"Su","year":"2010","journal-title":"BioDrugs"},{"key":"B63","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-016-0160-y","article-title":"Adjuvants for peptide-based cancer vaccines","volume":"4","author":"Khong","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-88","article-title":"HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial","volume":"11","author":"van Poelgeest","year":"2013","journal-title":"J Transl Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e012555","DOI":"10.1136\/jitc-2025-012555","article-title":"Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent\/metastatic HPV16-positive head and neck cancer","volume":"13","author":"Even","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1031439","article-title":"A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2\/3","volume":"4","author":"Greenfield","year":"2015","journal-title":"Oncoimmunology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1821-x","article-title":"Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination","volume":"65","author":"Coleman","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e005016","DOI":"10.1136\/jitc-2022-005016","article-title":"Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions","volume":"10","author":"Speetjens","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801634","article-title":"Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a type I IFN response","volume":"202","author":"Gandhapudi","year":"2019","journal-title":"J Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.6998","article-title":"Novel combination immunotherapy and clinical activity in patients with HPV-associated cancers: a nonrandomized clinical trial","volume":"11","author":"Floudas","year":"2025","journal-title":"JAMA Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20680","article-title":"Analyses of functions of an anti-PD-L1\/TGF\u03b2R2 bispecific fusion protein (M7824)","volume":"8","author":"Jochems","year":"2017","journal-title":"Oncotarget"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1349589","article-title":"A novel bifunctional anti-PD-L1\/TGF-\u03b2 trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells","volume":"6","author":"David","year":"2017","journal-title":"Oncoimmunology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1853","article-title":"The immunocytokine NHS-IL12 as a potential cancer therapeutic","volume":"5","author":"Fallon","year":"2014","journal-title":"Oncotarget"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605611","article-title":"Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia","volume":"102","author":"Daayana","year":"2010","journal-title":"Br J Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.043","article-title":"Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease","volume":"37","author":"Da Silva","year":"2019","journal-title":"Vaccine"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.617","article-title":"DNA vaccines","volume":"15","author":"Donnelly","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.18.1.927","article-title":"DNA vaccines: immunology, application, and optimization*","volume":"18","author":"Gurunathan","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0998-867","article-title":"Gene transfer into muscle by electroporation in vivo","volume":"16","author":"Aihara","year":"1998","journal-title":"Nat Biotechnol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.6.1075","article-title":"Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization","volume":"188","author":"Porgador","year":"1998","journal-title":"J Exp Med"},{"key":"B82","article-title":"Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene","volume":"60","author":"Chen","year":"2000","journal-title":"Cancer Res"},{"key":"B83","article-title":"Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes","volume":"63","author":"Hung","year":"2003","journal-title":"Cancer Res"},{"key":"B84","article-title":"Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand","volume":"61","author":"Hung","year":"2001","journal-title":"Cancer Res"},{"key":"B85","article-title":"Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen","volume":"61","author":"Hung","year":"2001","journal-title":"Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302252","article-title":"Comparison of HPV DNA vaccines employing intracellular targeting strategies","volume":"11","author":"Kim","year":"2004","journal-title":"Gene Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950016474","article-title":"Targeting human papillomavirus type 16 E7 to the endosomal\/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors","volume":"10","author":"Ji","year":"1999","journal-title":"Hum Gene Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204860","article-title":"Biological activities and molecular targets of the human papillomavirus E7 oncoprotein","volume":"20","author":"M\u00fcnger","year":"2001","journal-title":"Oncogene"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(03)00275-5","article-title":"Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe","volume":"21","author":"Trimble","year":"2003","journal-title":"Vaccine"},{"key":"B90","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1038\/ncomms6317","article-title":"Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients","volume":"5","author":"Kim","year":"2014","journal-title":"Nat Commun"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1513","article-title":"A phase II, prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3","volume":"26","author":"Choi","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.11.026","article-title":"A pilot study of pNGVL4a-CRT\/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2\/3 (CIN2\/3)","volume":"140","author":"Alvarez","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1725","article-title":"A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2\/3","volume":"15","author":"Trimble","year":"2009","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet (London England)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.02.031","article-title":"A phase 1 trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6\/E7 oncogenes after chemoradiation for cervical cancer","volume":"107","author":"Hasan","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.8.4.421","article-title":"Therapeutic human papillomavirus vaccines: current clinical trials and future directions","volume":"8","author":"Hung","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.21775\/cimb.022.113","article-title":"mRNA: a versatile molecule for cancer vaccines","volume":"22","author":"Diken","year":"2017","journal-title":"Curr Issues Mol Biol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.4161\/hv.25181","article-title":"A novel, disruptive vaccination technology","volume":"9","author":"Kallen","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/08982100902726820","article-title":"Liposome-based cationic adjuvant formulations (CAF): past, present, and future","volume":"19","author":"Christensen","year":"2009","journal-title":"J Liposome Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2004.11.011","article-title":"Polyethylenimine-based non-viral gene delivery systems","volume":"60","author":"Lungwitz","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.922301","article-title":"Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1629259","article-title":"HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory","volume":"8","author":"Grunwitz","year":"2019","journal-title":"Oncoimmunology"},{"key":"B104","doi-asserted-by":"publisher","first-page":"S680","DOI":"10.1016\/j.annonc.2024.08.1058","article-title":"999MO HARE-40: A phase I\/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma","volume":"35","author":"Ottensmeier","year":"2024","journal-title":"Ann Oncol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"S627","DOI":"10.1016\/j.annonc.2024.08.938","article-title":"877P Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCC","volume":"35","author":"Saba","year":"2024","journal-title":"Ann Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.04.036","article-title":"Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related Malignancies","volume":"32","author":"Wang","year":"2024","journal-title":"Mol Ther"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/srep22509","article-title":"Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours","volume":"6","author":"Bialkowski","year":"2016","journal-title":"Sci Rep"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.148933","article-title":"Self-amplifying mRNA nanovaccine encoding GM-CSF-fused HPV16 E7 enhances immunogenicity and therapeutic efficacy against cervical cancer","volume":"333","author":"Lin","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13046-026-03640-7","article-title":"Circular RNA-based HPV16 therapeutic vaccine elicits potent and durable antitumor immunity","volume":"45","author":"Zhou","year":"2026","journal-title":"J Exp Clin Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"B112","doi-asserted-by":"publisher","first-page":"e012090","DOI":"10.1136\/jitc-2025-012090","article-title":"mRNA-encoded mutant HPV16\/18 vaccines promote specific T-cell responses and synergize with anti-PD-1 checkpoint blockade in mediating therapeutic tumor regression in mice","volume":"13","author":"Zhang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"B114","article-title":"Live attenuated bacteria as vectors to deliver plasmid DNA vaccines","volume":"5","author":"Dietrich","year":"2003","journal-title":"Curr Opin Mol Ther"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-407190-2.00007-1","article-title":"Therapeutic cancer vaccines: past, present, and future","volume":"119","author":"Guo","year":"2013","journal-title":"Adv Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.036","article-title":"Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors","volume":"26","author":"Sewell","year":"2008","journal-title":"Vaccine"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.02.005","article-title":"Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7","volume":"28","author":"Adachi","year":"2010","journal-title":"Vaccine"},{"key":"B118","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/10611860400024219","article-title":"Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli","volume":"13","author":"Cortes-Perez","year":"2005","journal-title":"J Drug Target"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2018.10.043","article-title":"Protection against human papillomavirus type 16-induced tumors in C57BL\/6 mice by mucosal vaccination with Lactococcus lactis NZ9000 expressing E6 oncoprotein","volume":"126","author":"Taghinezhad-S","year":"2019","journal-title":"Microb Pathog"},{"key":"B120","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.omtm.2019.08.005","article-title":"Phase 1 safety and immunogenicity trial of recombinant lactococcus lactis expressing human papillomavirus type 16 E6 oncoprotein vaccine","volume":"15","author":"Taghinezhad-S","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2007.05.005","article-title":"Listeriolysin O: a phagosome-specific lysin","volume":"9","author":"Schnupf","year":"2007","journal-title":"Microbes Infect"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00554-6","article-title":"Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts","volume":"21","author":"Peters","year":"2003","journal-title":"Vaccine"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1186\/s40661-017-0046-9","article-title":"Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy","volume":"4","author":"Miles","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001235","article-title":"A randomized phase 2 study of ADXS11-001 listeria monocytogenes-listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer","volume":"28","author":"Basu","year":"2018","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.01.004","article-title":"Tolerability of ADXS11-001 lm-LLO listeria-based immunotherapy with mitomycin, fluorouracil, and radiation for anal cancer","volume":"100","author":"Safran","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1121338","article-title":"Systemic listeriosis following vaccination with the attenuated Listeria monocytogenes therapeutic vaccine, ADXS11-001","volume":"12","author":"Sacco","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.09.020","article-title":"Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients","volume":"32","author":"Kawana","year":"2014","journal-title":"Vaccine"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.03.250","article-title":"The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up","volume":"153","author":"Harper","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112981","article-title":"Phase Ib\/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers","volume":"191","author":"Borcoman","year":"2023","journal-title":"Eur J Cancer"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2014.024","article-title":"Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine","volume":"25","author":"Rosales","year":"2014","journal-title":"Hum Gene Ther"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0234","article-title":"Local HPV recombinant vaccinia boost following priming with an HPV DNA vaccine enhances local HPV-specific CD8+ T-cell\u2013mediated tumor control in the genital tract","volume":"22","author":"Sun","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"221ra13","DOI":"10.1126\/scitranslmed.3007323","article-title":"Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions","volume":"6","author":"Maldonado","year":"2014","journal-title":"Sci Transl Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.4110\/in.2021.21.e6","article-title":"Adenovirus vectors: excellent tools for vaccine development","volume":"21","author":"Chang","year":"2021","journal-title":"Immune Netw"},{"key":"B134","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ijc.30679","article-title":"Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease","volume":"141","author":"Khan","year":"2017","journal-title":"Int J Cancer"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31166","article-title":"Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8(+) T cell responses against HPV16 oncoproteins","volume":"142","author":"\u00c7uburu","year":"2018","journal-title":"Int J Cancer"},{"key":"B136","doi-asserted-by":"publisher","first-page":"18713","DOI":"10.1038\/s41598-019-55014-z","article-title":"A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins","volume":"9","author":"Hancock","year":"2019","journal-title":"Sci Rep"},{"key":"B137","doi-asserted-by":"publisher","first-page":"A513","DOI":"10.1136\/jitc-2021-SITC2021.483","article-title":"483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers","volume":"9","author":"Floudas","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B138","doi-asserted-by":"publisher","first-page":"e141912","DOI":"10.1172\/jci.insight.141912","article-title":"Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009","volume":"6","author":"Pellom","year":"2021","journal-title":"JCI Insight"},{"key":"B139","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/vaccines4040039","article-title":"Replicon RNA viral vectors as vaccines","volume":"4","author":"Lundstrom","year":"2016","journal-title":"Vaccines"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1662","article-title":"Vvax001, a therapeutic vaccine, for patients with HPV16-positive high-grade cervical intraepithelial neoplasia: A phase II trial","volume":"31","author":"Eerkens","year":"2025","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.732166","article-title":"Development and characterization of a novel non-lytic cancer immunotherapy using a recombinant arenavirus vector platform","volume":"11","author":"Lauterbach","year":"2021","journal-title":"Front Oncol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.2174\/138161205774414565","article-title":"Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy","volume":"11","author":"Santin","year":"2005","journal-title":"Curr Pharm Des"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02343-07","article-title":"Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial","volume":"82","author":"Santin","year":"2008","journal-title":"J Virol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.09.040","article-title":"HPV16\/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities","volume":"100","author":"Santin","year":"2006","journal-title":"Gynecol Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-003-0463-5","article-title":"Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients","volume":"129","author":"Ferrara","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2014.15.14.5909","article-title":"Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer--a feasibility study","volume":"15","author":"Ramanathan","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0353-4","article-title":"Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer","volume":"12","author":"Rahma","year":"2014","journal-title":"J Transl Med"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1136039","article-title":"Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases","volume":"12","author":"Skeate","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1586\/erv.13.23","article-title":"Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer","volume":"12","author":"Morrow","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B151","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.imlet.2008.12.006","article-title":"Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death","volume":"122","author":"Kim","year":"2009","journal-title":"Immunol Lett"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12620","article-title":"The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-\u03b2 receptor on dendritic cells potentiates tumour antigen-specific CD8+ T cell immunity","volume":"181","author":"Ahn","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0889","article-title":"CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo","volume":"66","author":"Chung","year":"2006","journal-title":"Cancer Res"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15776","article-title":"IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours","volume":"8","author":"Seo","year":"2017","journal-title":"Nat Commun"},{"key":"B155","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/jcm9010147","article-title":"Phase I study of a B cell-based and monocyte-based immunotherapeutic vaccine, BVAC-C in human papillomavirus type 16- or 18-positive recurrent cervical cancer","volume":"9","author":"Choi","year":"2020","journal-title":"J Clin Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1371353","article-title":"Efficacy and safety of BVAC-C in HPV type 16- or 18-positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I\/IIa study","volume":"15","author":"Choi","year":"2024","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0327-0","article-title":"T-cell receptor-engineered cells for the treatment of hematologic Malignancies","volume":"11","author":"Hossain","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201545849","article-title":"Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy","volume":"46","author":"Kelderman","year":"2016","journal-title":"Eur J Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.6566","article-title":"Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer","volume":"33","author":"Zsiros","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-018-0541-2","article-title":"Combined treatment with autologous CIK cells, radiotherapy and chemotherapy in advanced cervical cancer","volume":"25","author":"Li","year":"2019","journal-title":"Pathol Oncol Res"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3341","article-title":"Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6","volume":"21","author":"Draper","year":"2015","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.126722","article-title":"A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers","volume":"285","author":"Riemer","year":"2010","journal-title":"J Biol Chem"},{"key":"B165","doi-asserted-by":"publisher","first-page":"e99488","DOI":"10.1172\/jci.insight.99488","article-title":"Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model","volume":"3","author":"Jin","year":"2018","journal-title":"JCI Insight"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"key":"B167","doi-asserted-by":"publisher","first-page":"A336","DOI":"10.1136\/jitc-2022-SITC2022.0320","article-title":"320 Rapid identification of a TCR library targeting the HPV E6\/E7 oncoproteins to enable multi-TCR T-cell therapies for patients with HPV16+ epithelial cancers","volume":"10","author":"Bostick","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010337","article-title":"HLA-A*11:01-restricted CD8+ T cell immunity against influenza A and influenza B viruses in Indigenous and non-Indigenous people","volume":"18","author":"Habel","year":"2022","journal-title":"PloS Pathog"},{"key":"B169","doi-asserted-by":"publisher","first-page":"e004790","DOI":"10.1136\/jitc-2022-004790","article-title":"Identification of novel HLA-A*11:01-restricted HPV16 E6\/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy","volume":"10","author":"Xiong","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B170","doi-asserted-by":"publisher","first-page":"A413","DOI":"10.1136\/jitc-2023-SITC2023.0364","article-title":"364 Non-clinical development of T-Plex component TSC-200-A0201: a natural HPV16 E7-specific TCR-T cell therapy for the treatment of HPV16-positive solid tumors","volume":"11","author":"Jangalwe","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-3482","article-title":"Abstract 3482: Enhanced targeting of HPV positive cancers using gamma delta 1 T cells armored with an HPV E7-specific TCR: a novel approach to overcome HLA downregulation","volume":"85","author":"Mosquera","year":"2025","journal-title":"Cancer Res"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00722-1","article-title":"The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy","volume":"20","author":"Mensurado","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J Immunother Cancer"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3354","article-title":"CUE-101, a novel E7-pHLA-IL2-Fc fusion protein, enhances tumor antigen-specific T-cell activation for the treatment of HPV16-driven Malignancies","volume":"26","author":"Quayle","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.01.192","article-title":"A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3rd line and in combination with pembrolizumab in 1st line recurrent\/metastatic (R\/M) HPV16+ head and neck cancer patients","volume":"118","author":"Colevas","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B176","doi-asserted-by":"publisher","first-page":"A764","DOI":"10.1136\/jitc-2023-SITC2023.0674","article-title":"674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent\/metastatic HPV16+ head and neck cancer patients","volume":"11","author":"Chung","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.6013","article-title":"A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent\/metastatic HPV16+ head and neck cancer","volume":"41","author":"Chung","year":"2023","journal-title":"J Clin Oncol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5775696","article-title":"The role of TAMs in tumor microenvironment and new research progress","volume":"2022","author":"Feng","year":"2022","journal-title":"Stem Cells Int"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2022.101671","article-title":"Tumor associated macrophage in HPV(+) tumors: Between immunosuppression and inflammation","volume":"65","author":"Gorvel","year":"2023","journal-title":"Semin Immunol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1572195","article-title":"Chemotherapy-induced immunogenic cell death in combination with ICIs: a brief review of mechanisms, clinical insights, and therapeutic implications","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201734","article-title":"Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency","volume":"9","author":"Li","year":"2022","journal-title":"Adv Sci"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.5525","article-title":"Association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival","volume":"35","author":"Gerritsen","year":"2026","journal-title":"J Clin Oncol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.01.049","article-title":"Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16\/18 E6E7)","volume":"22","author":"Davidson","year":"2004","journal-title":"Vaccine"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/612823","article-title":"Disruption of HPV16-E7 by CRISPR\/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells","volume":"2014","author":"Hu","year":"2014","journal-title":"BioMed Res Int"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0250","article-title":"Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16\/18-positive cervical cancer cells","volume":"20","author":"Ding","year":"2014","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78206","article-title":"TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical Malignancy","volume":"125","author":"Hu","year":"2015","journal-title":"J Clin Invest"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.03.010","article-title":"Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes","volume":"98","author":"Zhou","year":"2013","journal-title":"Antiviral Res"},{"key":"B188","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jconrel.2016.03.016","article-title":"Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes","volume":"231","author":"Nishida","year":"2016","journal-title":"J Control release Off J Control Release Soc"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28144","article-title":"CRISPR\/Cas9-HPV-liposome enhances antitumor immunity and treatment of HPV infection-associated cervical cancer","volume":"95","author":"Zhen","year":"2023","journal-title":"J Med Virol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1748797","article-title":"PD-L1 testing and assessment: Practical considerations for oncologist and pathologist","volume":"45","author":"Pasricha","year":"2022","journal-title":"Indian J Med Paediatr Oncol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines14070599","article-title":"Therapeutic cancer vaccines: Mechanisms, clinical progress, and future directions","volume":"14","author":"Wilson","year":"2026","journal-title":"Vaccines"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125581","article-title":"Understanding HPV-induced cancers and investigating the barriers faced by low- and middle-income countries in prevention and treatment","volume":"26","author":"Aleezada","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B193","doi-asserted-by":"publisher","first-page":"e004232","DOI":"10.1136\/jitc-2021-004232","article-title":"ISA101 and nivolumab for HPV-16(+) cancer: updated clinical efficacy and immune correlates of response","volume":"10","author":"Sousa","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.6003","article-title":"Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent\/metastatic (R\/M) HPV16-positive oropharyngeal cancer (OPC)","volume":"42","author":"Even","year":"2024","journal-title":"J Clin Oncol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.64898\/2026.01.09.26343801","article-title":"A randomized double-blind placebo-controlled phase I\/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck cancer recurrence","author":"Bivens","year":"2026","journal-title":"medRxiv Prepr Serv Heal Sci"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2634","article-title":"Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2\/3","volume":"42","author":"Nakagawa","year":"2024","journal-title":"J Clin Oncol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.6012","article-title":"Safety and efficacy of immune checkpoint inhibitor (ICI) na\u00efve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC)","volume":"41","author":"Price","year":"2023","journal-title":"J Clin Oncol"},{"key":"B198","doi-asserted-by":"publisher","first-page":"100786","DOI":"10.1016\/j.iotech.2024.100786","article-title":"157P Preliminary results of a multicentric randomized phase I\/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)","volume":"24","author":"Even","year":"2024","journal-title":"Immuno-Oncology Technol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"102716","DOI":"10.1016\/j.eclinm.2024.102716","article-title":"GX-188E DNA vaccine plus pembrolizumab in HPV 16- and\/or 18-positive recurrent or advance cervical cancer: a phase 2 trial","volume":"74","author":"Lim","year":"2024","journal-title":"eClinicalMedicine"},{"key":"B200","doi-asserted-by":"publisher","first-page":"A757","DOI":"10.1136\/jitc-2023-SITC2023.0667","article-title":"667 Predictive value of circulating tumor DNA in patients with advanced HPV16-positive cervical cancer treated with VB10.16 in combination with atezolizumab","volume":"11","author":"Bousquet","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B201","doi-asserted-by":"publisher","first-page":"e010827","DOI":"10.1136\/jitc-2024-010827","article-title":"Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study","volume":"13","author":"Hillemanns","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1987","article-title":"Safety and efficacy of MEDI0457 plus durvalumab in patients with human papillomavirus\u2013associated recurrent\/metastatic head and neck squamous cell carcinoma","volume":"29","author":"Aggarwal","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.06.493","article-title":"Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: an NRG oncology\/gynecologic oncology group study","volume":"158","author":"Huh","year":"2020","journal-title":"Gynecol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1897025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:06:20Z","timestamp":1789553180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1897025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":203,"alternative-id":["10.3389\/fimmu.2026.1897025"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1897025","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1897025"}}